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Revised Adult Treatment Panel III Guidelines and
Cardiovascular Disease Mortality in Men Attending a
Preventive Medical Clinic
Chris I. Ardern, MSc; Peter T. Katzmarzyk, PhD; Ian Janssen, PhD;
Timothy S. Church, MD, MPH, PhD; Steven N. Blair, PED
Background—National Cholesterol Education Program Adult Treatment Panel III guidelines recommend therapeutic
lifestyle changes (TLC) and drug therapy to reduce cardiovascular disease (CVD) risk. These guidelines have been
revised recently (ATP III-R); however, the risk of CVD mortality within each intervention window and the effects of
cardiorespiratory fitness (CRF) and metabolic syndrome on CVD mortality within the framework of the guidelines are
unknown.
Methods and Results—Risk factor and CRF data from 19 125 men (aged 20 to 79 years) who attended a preventive
medical clinic between 1979 and 1995 were used. Mortality follow-up was completed until December 31, 1996.
Participants were assigned to ATP III-R groups (LDL-C goal, TLC initiation, and drug consideration), and risk of CVD
mortality was assessed by Cox proportional hazards regression. There were 179 CVD deaths over an average 10.2 years
of follow-up. Compared with the LDL-C goal group, men in the TLC initiation and drug consideration groups had an
elevated risk of CVD mortality (TLC initiation: HR2.65, 95% CI 1.67 to 4.19; drug consideration: HR6.44, 95%
CI 4.49 to 9.25). Compared with LDL-C goal/fit, CVD mortality risk was higher in the LDL-C goal/unfit (4.8, 2.5 to
9.1), TLC initiation/fit (3.0, 1.7 to 5.3), TLC initiation/unfit (7.5, 3.7 to 15.2), drug consideration/fit (7.2, 4.6 to 11.4),
and drug consideration/unfit (14.9, 9.1 to 24.4) groups. A similar gradient was observed for metabolic syndrome across
intervention windows.
Conclusions—Men eligible for TLC or drug consideration under ATP III-R were at elevated risk of CVD mortality
compared with men who met the LDL-C goal. Furthermore, men who were physically fit or who did not have the
metabolic syndrome had a lower risk of CVD mortality. (Circulation. 2005;112:1478-1485.)
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Global risk assessment and physician treatment algo-rithms are accepted aids to decision making in cardio-
vascular medicine, owing in large part to the clinical guide-
lines of the National Cholesterol Education Program (NCEP)
Expert Panel. In 2001, the third NCEP report (Adult Treat-
ment Panel; ATP III) recommended focusing on LDL cho-
lesterol (LDL-C) as the primary target for coronary heart
disease (CHD) risk reduction.1 These guidelines have since
been revised (ATP III-R)2 to incorporate the results of recent
“statin” (3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors) trials and their efficacy in lowering LDL-C. Like
the previous version, the revised guidelines also emphasize
the importance of therapeutic lifestyle change (TLC; diet,
physical activity, and weight management) in the prevention
and treatment of atherosclerosis in primary and secondary
care, a position that has been reinforced by a statement from
the American Heart Association’s Council on Clinical
Cardiology.3
The current guidelines use an evidence-based global risk
assessment approach to identify immediate and long-term
risk, while identifying opportunities for intervention. To
apply the ATP III-R guidelines, the number of traditional
CHD risk factors is counted (0 to 5) and used to classify a
patient into a preliminary risk status category (lower, mod-
erate, moderately high, and high risk). Within each risk status
category, patients are classified into 1 of 3 intervention
groups based on their LDL-C level: (1) at or below LDL-C
goal (“LDL-C goal”); (2) initiate TLC (“TLC initiation”), and
(3) consider drug therapy (“drug consideration”). Beyond
LDL-C lowering, ATP III-R also recognizes the importance
of the metabolic syndrome and physical activity in defining
CHD risk. Furthermore, within the high-risk status group,
universally low LDL-C targets are recommended for all
patients with diabetes, those with high Framingham risk
scores, and those with previous coronary events.
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To date, little is known about the clinical application of these
guidelines. Given the widespread adoption of previous NCEP
reports, a critical investigation of the effectiveness of ATP III-R
guidelines in predicting hard end points such as cardiovascular
disease (CVD) mortality is both warranted and timely.
The primary aim of the present study was to quantify the
association across baseline ATP III-R group classification
(LDL-C goal, TLC initiation, and drug consideration) with
CVD mortality. Secondary aims of this study were to (1)
explore the influence of the metabolic syndrome and cardio-
respiratory fitness (CRF) on CVD mortality risk within the
ATP III-R classification groups and (2) explore the risk of
CVD mortality across subgroups of the high-risk category.
Methods
Participants and Mortality Ascertainment
All men who attended the Cooper Clinic (Dallas, Tex) for a
preventive medical examination and a maximal exercise test between
1979 and December 31, 1995 were eligible for inclusion in the
Aerobics Center Longitudinal Study (ACLS). Although there are
women participants in the ACLS, the number of CVD deaths is at
present insufficient to perform the analyses reported here. ACLS
men are predominantly white, college- or university-educated pro-
fessionals. Follow-up was available until December 31, 1996, or
death. Thus, the cohort used in the present analysis can be considered
to be largely in the prestatin era, before a marked increase in statin
use in the late 1990s. Mortality was ascertained by linkage with the
US National Death Index, and official death certificates were
obtained from each state’s public health department. Primary causes
of death were coded by a nosologist according to the Ninth Revision
of the International Classification of Disease Clinical Modification
(ICD-9),4 and CVD mortality was defined as “diseases of the
circulatory system” (390 to 448.9). The study protocol was reviewed
and approved by the Institutional Review Board of The Cooper
Institute on an annual basis. All men provided written informed
consent.
Complete data were available for classification of 23 437 men into
ATP III-R treatment categories within the age range (20 to 79 years)
to which the adapted Framingham risk algorithm applies. To reduce
the potential influence of covert disease on ATP III-R classification,
the final sample was limited to 19 125 men who were free of cancer
at baseline and had at least 1 year of follow-up. The 4312 men who
were excluded tended to be older (mean age 45.9 versus 43.2 years;
t14.8, P0.0001) than the men in the final study sample; however,
there were no differences in the prevalence of being physically unfit
between the 2 groups (both 13.8%, 20.14, PNS).
Clinical Measurements
Participants reported to the Cooper Clinic after a 12-hour fast for
examination by one of the clinic’s physicians. All men completed a
general health habit questionnaire detailing personal and family
medical history in addition to a demographic profile before under-
going a complete clinical battery of blood chemistry, resting blood
pressure, and anthropometric measurements. Blood pressures were
obtained with a mercury sphygmomanometer by auscultatory meth-
ods, and plasma was drawn for total and HDL cholesterol (HDL-C)
determination. The Friedewald equation was used to calculate
LDL-C, where triglycerides 4.52 mmol/L.5 All assays were con-
ducted by Cooper Clinic technicians in accordance with the Centers
for Disease Control and Prevention lipid standardization program
(coefficients of variation 3%).6
CRF was assessed by a maximal treadmill test (according to a
modified Balke protocol)7 that began at a speed of 88 m/min and 0%
elevation and increased to 2% on completion of the first minute. The
elevation was increased by 1% each subsequent minute until 25
minutes had passed, at which point elevation was held at 25% and
the speed was increased by 5.4 m/min each minute. Time to
volitional fatigue (r0.92 with directly measured V̇O2max)8 was
translated into metabolic equivalents [METs(1.44treadmill time/
6014.99)/3.5]. Age-adjusted METs were then divided into fifths;
the bottom quintile (20th percentile) was considered “unfit” and
the top 4 quintiles (21st to 100th percentile) “fit.” These fitness
criteria are from previous reports on the cohort.9
Body weight and height were measured on a standard physician’s
balance beam scale and stadiometer, and the body mass index (BMI)
was calculated (kg/m2). Waist circumference (WC; cm) was mea-
sured with an inelastic anthropometric tape at the level of the
umbilicus.
Placement Into ATP III-R Groups
As described in Figure 1, placement into ATP III-R groups involves
4 steps. The first step in identifying LDL-C targets that alter CHD
risk is counting of core risk factors.2 Risk factors that modify the
LDL-C goals for ATP III-R treatment are as follows: (1) age 45
years,(2) family history of premature CHD (myocardial infarction
[MI] or sudden death of male first-degree relative before age 55
years or first-degree female relative before age 65 years), (3) current
cigarette smoking, (4) hypertension (140/90 mm Hg or a history of
physician-diagnosed hypertension), and (5) low HDL-C
(1.03 mmol/L); if HDL-C is 1.55 mmol/L, 1 risk factor is
removed from the count. Approximately 24% of men had 0 risk
factors (an additional 4% also had a high HDL-C level that qualified
as a negative risk factor), 34.5% had 1 risk factor, and 37.5% had 2
risk factors. In the second step of ATP III-R, men with 2 risk
factors are indicated for an assessment of their 10-year risk of “hard”
coronary events (MI and coronary-related death) with the adapted
Framingham algorithm, an index of CHD risk based on categories of
age, age-adjusted total cholesterol, HDL-C, systolic blood pressure
(treated and untreated), and age-adjusted cigarette smoking (0non-
smoker, 1any in past month). Of men with 2 core risk factors, the
median Framingham 10-year risk of coronary events was 8% (range
1% to 30%), with 32.7% and 11.7% having a 10% to 20% and 20%
10-year risk, respectively. In the present study, ACLS men only had
Figure 1. ATP III-R treatment eligibility
groups. The present study compared
the risk of CVD mortality across LDL-C
goal, TLC initiation, and drug therapy
consideration groups. Adapted from
Grundy et al.2 See Methods for further
details. *Almost all people with 0 or 1
risk factor have a 10-year risk 10%,
and 10-year risk assessment in people
with 0 or 1 risk factor is thus not nec-
essary. To convert LDL-C in mmol/L to
mg/dL, multiply by a factor of 38.67.
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1 baseline blood lipid measurement rather than the recommended
average of two,2 and cigarette smoking was based on self-report
(0quitter or nonsmoker, 1current smoker). Also, information on
use of blood pressure medication such as -blockers or diuretics was
not universally available, but information on physician-diagnosed
hypertension was available in the medical record. Finally, family
history of premature coronary events was defined as a parental heart
attack, bypass surgery, or angina under the age of 50 years.
In the third step of the ATP III-R, 4 CHD risk categories are
identified to indicate target thresholds for LDL-C lowering: men
with (1) 0 to 1 risk factor (lower risk); (2) 2 risk factors with 10%
10-year CHD risk (moderate risk); (3) 2 risk factors and 10% to
20% 10-year CHD risk (moderately high risk); and (4) established
CHD or CHD risk equivalents (other vessel disease, diabetes, 20%
10-year CHD risk; high risk). In the ACLS, men were coded as
diabetic (n470; 2.5%) in the presence of high fasting blood glucose
(7.0 mmol/L) or a self-reported previous physician diagnosis of
diabetes. A previous heart attack was self-reported in 326 men (1.7%
of sample), and another 335 men (1.8%) had a 10-year CHD risk
20%. Multiple CHD risk equivalents were found in 53 men; thus,
1076 men (5.6% of the sample) were automatically placed in the
high-risk category for which aggressive LDL-C lowering treatment
is recommended.
In the final step of the ATP III-R, men are assigned to LDL-C
goal, TLC initiation, or drug consideration groups on the basis of the
LDL-C target of each participant’s respective core risk factor
category (Figure 1). The LDL-C thresholds for TLC initiation were
4.14, 3.36, 3.36, and 2.59 mmol/L across the low-, moderate-,
moderately high-, and high-risk categories, respectively. Corre-
sponding LDL-C thresholds for drug consideration (4.91, 4.14, 3.36,
and 2.59 mmol/L) were also applied and represent a lowering of the
high-risk LDL-C goal for drug consideration (from 3.36 to
2.59 mmol/L) in ATP III-R, with an optional LDL-C goal of
1.81 mmol/L in those at very high immediate risk.
Secondary Targets of ATP III-R
Secondary targets of risk reduction include TLC approaches to the
metabolic syndrome, a constellation of atherogenic risk factors, once
elevated LDL-C has been addressed. According to the ATP III
working definition,1 the metabolic syndrome is defined by 3 or more
of (1) abdominal obesity (WC 102 cm), 2) high triglycerides
(1.69 mmol/L), (3) low HDL-C (1.03 mmol/L), (4) high blood
pressure (130/85 mm Hg), or (5) high fasting blood glucose (
6.11 mmol/L). According to the revised guidelines, TLC initiation is
automatically indicated in the presence of (1) high triglycerides
(2.26 mmol/L), (2) high BMI (30 kg/m2), (3) physical inactivity,
or (4) the metabolic syndrome, when core risk factor status is
moderately high or high. In application of ATP III-R to the ACLS
cohort, we have substituted the lowest quintile of age-adjusted METs
(physically unfit) for “physical inactivity.” Indeed, previous research
has indicated that CRF is a good marker for physical activity levels
in the months preceding a fitness test.10
Statistical Analysis
Survival characteristics (follow-up length and crude and adjusted
CVD death rates/10 000 man-years) of each ATP III-R group were
generated, and survival curves were estimated by the Kaplan-Meier
method and compared with log-rank statistics. Deaths that were not
cardiovascular in origin were treated as right-censored observations.
The proportional hazards assumption of the log-linear Cox regres-
sion model was assessed by visual inspection of negative log by
negative log survival plots, and a formal test of proportionality with
age- and time-dependent ATP III-R groups was conducted. This test
revealed no violation of proportional hazard assumptions (Wald
23.43, df3, P0.33).
To investigate the primary study aims, risk of CVD mortality
across baseline ATP III-R groups was assessed by entering dummy
coded TLC initiation (0no; 1TLC initiation) and drug consider-
ation (0no; 1drug consideration) variables into the time-fixed
regression model,11 with adjustment for year of examination. Sec-
ond, to examine the persistent effect of age, interactions with ATP
III-R groups were probed, and age-stratified (20 to 39 years; 40 to 59
years; and 60 to 79 years) analyses were conducted.
To explore our secondary aims, we fit Cox regression models
under 2 conditions: (1) ATP III-R without inclusion of the metabolic
syndrome as an automatic inclusion for TLC initiation in the
moderately high and high core risk factor categories but with
cross-classification into “metabolic syndrome” and “no metabolic
syndrome” within each ATP III-R group, and (2) ATP III-R without
inclusion of “unfit” as an automatic inclusion, with cross-
classification into “unfit” and “fit” within the ATP III-R groups, as
above. Furthermore, to provide insight into the relative risk across
subgroups of the risk equivalents in the high core risk factor
category, men were classified into 4 mutually exclusive subsets,
representing men with (1) previous coronary events, (2) diabetes, (3)
Framingham risk scores 20%, and (4) 2 risk equivalents,
compared with lower, moderate, and moderately high categories
combined. Finally, the additive effects of BMI, WC, and CRF on
CVD mortality beyond ATP III-R classification were assessed in 6
subsequent Cox regression models of increasing complexity. All
statistical analysis were conducted in SAS version 8.0, and statistical
significance was set at an -level of 0.05.
Results
Description of Study Population
Table 1 presents the baseline characteristics of the sample. In
this sample, 58% were classified as being in the LDL-C goal
group, whereas 18% were eligible for TLC initiation and 24%
for drug consideration. As expected, there was a positive
gradient of the component risk factors (eg, 10-year risk of
CHD, metabolic syndrome, diabetes, and cigarette smoking)
across the LDL-C goal, TLC initiation, and drug consider-
ation groups. There was also a strong age-related gradient in
the prevalence of drug consideration.
Survival Analysis by ATP III-R Categories
There were a total of 489 deaths, 179 of which were
cardiovascular in origin. CHD represented 60% of all CVD
deaths and a proportionately similar (PNS) number across
ATP III-R groups (Table 2). Of all CHD deaths, the most
common causes of death were acute MI (ICD-9 410; 67
deaths) and coronary atherosclerosis (ICD-9 414; 46 deaths).
Differences in survival probabilities across LDL-C goal,
TLC initiation, and drug consideration groups (log-rank
2134.3, df2, P0.001) are shown in Figure 2 and
represent approximately 4, 9, and 23 deaths per 10 000
man-years, respectively. Overall, after adjustment for year of
examination, the TLC initiation (hazard ratio [HR]2.65,
95% CI 1.67 to 4.19) and drug consideration (HR6.44, 95%
CI 4.49 to 9.25) groups were at markedly elevated risk of
CVD mortality compared with the LDL-C goal group (Figure
3A). The observed HRs were attenuated by the addition of
age to the model. Evidence for age as an effect modifier was
also apparent. There was a significant age-by-drug consider-
ation interaction, whereas age did not modify the TLC
initiation–mortality relationship. Drug consideration in the
40-to-59-year-old group was associated with a greater rela-
tive risk of CVD mortality than either the younger or older
age groups (Figure 3B). Although ATP III-R is intended to
prevent CHD-related morbidity and mortality, risk of
all-cause mortality was also elevated in the TLC initiation
(HR1.57, 95% CI 1.22 to 2.01) and drug consideration
(HR2.80, 95% CI 2.29 to 3.40) groups by comparison to
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the LDL-C goal group, after adjustment for year of
examination.
Influence of Secondary Targets on Survival
When we compared risk of CVD mortality for men with and
without the metabolic syndrome within ATP III-R categories,
men with the metabolic syndrome in the drug consideration
group (HR1.51, 95% CI 1.02 to 2.23) but not those in the
LDL-C goal (HR1.93, 95% CI 0.86 to 4.32) or TLC
initiation (HR1.06, 95% CI 0.43 to 2.61) groups, were at a
significantly greater risk of CVD mortality than those without
the metabolic syndrome. Figure 4A depicts a trend for higher
CVD mortality across strata of ATP III-R and the metabolic
syndrome. Thus, compared with men in the LDL-C goal/no
metabolic syndrome group, men in the drug consideration/
metabolic syndrome group (HR8.2, 95% CI 5.3 to 12.8)
were at greatest risk of CVD mortality.
Within ATP III-R categories, physically unfit men in the
LDL-C goal (HR5.61, 95% CI 3.06 to 10.29) and drug
consideration (HR2.07, 95% CI 1.40 to 3.08) groups were







Age, y 40.69.2 44.29.0§ 48.99.2#
BMI, kg/m2 25.73.4 26.93.5§ 27.33.6#
WC, cm 91.510.1 95.410.0§ 97.310.3#
Total cholesterol, mmol/L 4.870.71 5.870.69§ 6.481.15#
LDL-C, mmol/L 3.070.59 4.000.60§ 4.591.08#
HDL-C, mmol/L 1.230.31 1.130.28§ 1.070.26#
Triglycerides, mmol/L 1.250.71 1.610.82§ 1.790.81#
Systolic blood pressure, mm Hg 118.311.8 120.912.5§ 123.714.2#
Diastolic blood pressure, mm Hg 78.98.8 81.69.3§ 83.49.7#
Framingham 10-year CHD risk, % 33 54§ 127#
Prevalence, %
Age category
20–39 y 74.6 14.5§ 10.8#
40–59 y 49.7 20.4§ 29.9#
60–79 y 33.0 16.1§ 50.9#
Metabolic syndrome 9.4 22.5§ 33.0#
Current smoker* 12.2 14.6§ 32.4#
No alcohol consumption† 25.0 27.1 26.5
Obese (BMI 30 kg/m2) 9.7 17.1§ 19.0
High WC (102 cm) 13.9 23.1§ 28.3#
Physically unfit‡ 10.0 15.1§ 22.1#
Diabetes 0.2 1.2§ 8.9#
Plus-minus values are meanSD.
*Self-reported current cigarette smokers.
†Self-report of no regular weekly alcohol consumption.
‡Top four fifths of age-adjusted METs (21st to 100th percentile).
One-way ANOVA across ATP III-R categories (Scheffe planned contrasts P0.01); 2 test between
groups (Bonferroni corrected pairwise comparisons P0.01): §TLC initiation vs LDL-C goal; drug
consideration vs LDL-C goal; #drug consideration vs TLC initiation.









Hypertensive disease (401–404) 2 0 4 6
CHD (410–414) 24 24 65 113
Diseases of pulmonary circulation (415–417) 0 0 1 1
Other forms of heart disease (420–429) 10 8 17 35
Cerebrovascular disease (430–438) 4 1 12 17
Diseases of arteries, arterioles, and
capillaries (440–448)
1 0 6 7
CVD-related deaths 41 33 105 179
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at significantly increased risk of CVD mortality compared
with fit men, whereas the relationship was not significant in
the TLC initiation group (HR1.88, 95% CI 0.83 to 4.26). A
gradient of increasing risk of CVD mortality emerged both
within and between CRF categories such that men in the drug
consideration/unfit group were at markedly elevated risk
(HR14.89, 95% CI 9.11 to 24.35) compared with men in
the LDL-C goal/fit group (Figure 4B).
Table 3 describes the influence (per SD) of adiposity (BMI
and WC) and CRF on risk of CVD mortality in the TLC
initiation and drug consideration groups by comparison with
the LDL-C goal group. Owing to collinearity between BMI
and WC (r0.86), no model included both BMI and WC. In
separate models, BMI and WC moderately attenuated the risk
of CVD mortality associated with TLC initiation and drug
consideration status; however, the inclusion of METs in a
separate model resulted in an approximate 50% reduction in
the risk associated with drug consideration. The addition of
either BMI or WC to models that already included METs did
not further reduce risk of CVD mortality associated with TLC
initiation or drug consideration.
To investigate whether CVD mortality risk was similar
across the high core risk factor subgroups, we compared
coronary risk equivalents. By comparison with lower-,
moderate-, and moderately high–risk men combined, those
with a combination of 2 or more risk equivalents were at
markedly elevated risk of CVD mortality (HR28.9, 95% CI
14.7 to 57.0), followed by those who reported a previous
coronary event (HR14.6, 95% CI 9.7 to 22.1), diabetics
(HR6.3, 95% CI 3.7 to 10.8), and men with a high
Framingham risk score (HR4.5, 95% CI 2.3 to 9.0; Figure
5). Across high-risk men, 47% of the CVD deaths occurred in
those reporting a previous coronary event, 25% in diabetics,
and 15.8% in men with a high Framingham risk score, and the
remaining 12.5% were men with multiple risk equivalents.
There were also differences in the cause of death within each
subgroup, with ischemic events being most common in men
reporting a previous coronary event.
Discussion
Primary Aims
Results of this study indicate that the relative risk of CVD-
related mortality was more than twice as high in men in the
TLC initiation group at baseline and almost 7-fold higher in
Figure 2. Kaplan-Meier survival proba-
bility across baseline ATP III-R risk cat-
egories. Censored % is the percentage
of the sample who were survivors or
those who died of causes that were
not cardiovascular in origin. Log-rank
2134.3, df2, P0.001.
Figure 3. A, Comparison of risk of CVD mortality by baseline
ATP III-R treatment groups. B, Comparison of risk of CVD mor-
tality in drug consideration vs LDL-C goal groups across age
categories. All models were adjusted for year of examination.
Error bars represent 95% CIs.
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men eligible for drug consideration under ATP III-R. Given
that approximately one fourth of Americans (aged 20 to 79
years) were eligible for aggressive lipid-lowering therapy
under ATP III,12 lowering the threshold for consideration of
lipid-lowering drug therapy in those at high immediate and
long-term risk (ie, ATP III-R) is likely to have important
implications for both population health and healthcare utili-
zation. In the present study, the relative risk of CVD mortality
in men in the drug consideration group was higher when the
ATP III-R guidelines were applied (HR6.44, 95% CI 4.49
to 9.25) by comparison with the original ATP III guidelines
(HR4.75, 95% CI 3.39 to 6.65), which suggests that the
new criteria are effective at identifying men at a high risk of
CVD mortality.
Secondary Aims
In 2001, ATP III released a working definition of the
metabolic syndrome that is now included within ATP III-R as
a target for TLC in individuals with moderately high and high
core risk factor status. The inclusion of the metabolic syn-
drome as a therapeutic target of global risk assessment is an
important advance in treatment for the estimated 25% of the
US population that has the metabolic syndrome.13 In ACLS
men, 45% of those with the metabolic syndrome were in the
Figure 4. Risk of CVD mortality across ATP III-R treatment groups and metabolic syndrome (MetS; A) and physical fitness groups (B).
*Adjusted for year of examination. Unfit indicates lowest 20% of age-adjusted treadmill METs; Fit, top 80%. Values are HRs (95% CIs).
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drug consideration group compared with an estimated eligi-
bility for drug consideration of 39.2% among Americans with
the metabolic syndrome.14 Because LDL-C is not always
elevated in those with the metabolic syndrome, inclusion of
the metabolic syndrome in ATP III-R global risk assessment
is a potentially essential element to identify individuals at
elevated risk of CHD.14 In the ACLS, cross-classification of
those with and without the metabolic syndrome demonstrates
a trend toward increased risk of CVD mortality across ATP
III-R strata. Compared with healthy men, the risk of CVD
mortality has been shown to be 2-fold greater15,16 when the
metabolic syndrome is present, similar to the results present-
ed in Figure 4.
Results from the present study also suggest that within a
given ATP III-R risk category, CRF is associated with a 50%
lower risk of CVD mortality. The amount of physical activity
associated with being in the physically fit group in the present
study is approximately 4 to 5 bouts of 30 minutes’ duration
(equivalent to walking between 130 and 138 minutes per
week),17 which is consistent with recommendations from the
Surgeon General’s Report on Physical Activity and Health.18
It is also clear that the optimal approach to improving total
cholesterol, LDL-C, triglycerides, blood pressure, blood glu-
cose, and insulin resistance should include lifestyle modifi-
cation.2,19 Despite the acknowledged genetic contributions to
CRF, physical activity is the only way by which an individual
can increase his or her CRF; thus, despite difficulties with
long-term physical activity intervention, it continues to be a
necessary component to lowering long-term CVD risk. This
reinforces our position that physical activity and CRF should
be emphasized as a concomitant therapy in both TLC initia-
tion and drug consideration groups.
Subset analysis of CHD risk equivalents in men in the
high-risk category also suggests that all CHD risk equivalents
may not be equal. Here, we report that relative risk of CVD
mortality is highest in men with a previous coronary event
and lowest in those with a high Framingham risk score.
However, this analysis should be viewed as exploratory; in
addition to small sample sizes in the subgroup analysis, it is
also not yet fully clear whether more aggressive LDL-C
treatment targets or different therapeutic approaches can
improve CVD outcomes in each of the above subgroups.
Study Limitations
This study has some limitations that warrant recognition. We
were unable to address the potential influence of prescription
drug use on ATP III-R classification and subsequent mortal-
ity. Even though data for the present study were ascertained
in the prestatin era, it is possible that other lipid-lowering
drugs may have influenced the observed relationships. At
baseline, 25% of men reported taking a medication other
than insulin. Although medication use was an independent
predictor of CVD mortality when included in a model with
ATP III-R categories (HR2.55, 95% CI 1.41 to 4.61), its
inclusion as a covariate did not alter the relationship between
ATP III-R categories and CVD mortality. Given that higher-
risk men in this cohort with excellent access to medical care
would perhaps be more likely to receive pharmacological
treatments and coronary revascularization, the lack of com-
plete data on CVD morbidity would likely bias the results
toward the null.
Because only baseline measurements were used, it is
unclear what changes in lifestyle factors or medical history
TABLE 3. Contribution of BMI, WC, and CRF (METs) to Risk of CVD Mortality in TLC Initiation and Drug
Consideration, Compared With Men in the LDL-C Goal Group
TLC Initiation* Drug Consideration* BMI WC METs
Model 1 2.65 (1.67–4.19) 6.44 (4.49–9.25)
Model 2 2.49 (1.57–3.95) 5.93 (4.11–8.56) 1.20 (1.05–1.38)
Model 3 2.41 (1.52–3.82) 5.60 (3.87–8.09) 1.30 (1.14–1.49)
Model 4 1.85 (1.16–2.93) 3.01 (2.06–4.40) 0.35 (0.30–0.42)
Model 5 1.88 (1.18–2.98) 3.03 (2.08–4.43) 0.86 (0.74–0.99) 0.33 (0.28–0.40)
Model 6 1.88 (1.18–2.99) 3.05 (2.09–4.46) 0.89 (0.77–1.03) 0.34 (0.28–0.40)
Results are HR (95% CI) and are expressed per SD of BMI (kg/m2), WC (cm), and METs.
*All models include TLC initiation and drug consideration groups compared with LDL-C goal group (referent not shown).
Because of multicollinearity, BMI and WC are presented in separate models with METs.
Model 1 included year of examination as a covariate; Model 2, BMI and year of examination as covariates; Model 3, WC and year
of examination as covariates; Model 4, METs and year of examination as covariates; Model 5, BMI, METs, and year of examination
as covariates; and Model 6, WC, METs, and year of examination as covariates.
Figure 5. Subset analysis of ATP III-R
risk equivalents for CVD mortality, by
comparison with lower-risk men com-
bined. Within the pooled referent group
(lower, moderate, and moderately high
risk), there were 17 941 men, and
within the risk equivalent group, there
were 1184 men (diabetics: n470; pre-
vious coronary events: n326; 20%
10-year risk: n335; 2 risk equiva-
lents: n53). Values are HRs (95%
CIs).
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occurred over the follow-up period and how these changes
influenced the observed relationships. Additionally, the
ACLS is composed of predominantly non-Hispanic white,
college- or university-educated, upper-middle-class men,
which limits the generalizability of the findings. However,
the proportion of the sample in the drug consideration group
in the present study (24%) is similar to the 26% that has been
reported for American men for aggressive lipid-lowering
therapy.12 The number of deaths among women in the ACLS
is not yet sufficient to perform parallel analyses.
Finally, although the NCEP guidelines are intended to
identify target thresholds that lower atherosclerosis and CHD
risk, we elected to predict all CVD deaths. In a post hoc
analysis, we fit a Cox regression model, adjusted for year of
examination, to CHD-related mortality (ICD-9 410 to 414).
Results were similar to those seen in the CVD analysis
(LDL-C goal HR1.00, TLC initiation HR3.30 [95% CI
1.87 to 5.80], and drug consideration HR6.85 [95% CI 4.29
to 10.94]). Future studies should address these issues with
incident CVD and specific categories of CVD (eg, CHD and
stroke).
Summary
The present study supports the evidence-based clinical update
of the NCEP and indicates that inclusion of the metabolic
syndrome as a secondary target of cardiovascular risk reduc-
tion in men is appropriate. However, these data also suggest
that the risk of CVD mortality may not be uniform across
CHD risk equivalents in high-risk men. The inclusion of
physical inactivity as an automatic rationale for TLC initia-
tion in moderately high- and high-risk categories is an
important advance in ATP III-R risk prediction. Given the
magnitude of the relative risk associated with the additional
stratification by CRF, all patients should be encouraged to be
physically active and to maintain adequate levels of physical
fitness.
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